Immix Biopharma, Inc. · NASDAQ:IMMX
Immix Biopharma — ASCO 2025
13 slides from Immix Biopharma's conference presentation, Jun 3, 2025
Slide 1: Initial Safety and Efficacy Data from Nexicart-2, First U.S. CAR-T Trial in R/R AL Amyloidosis
Initial Safety and Efficacy Data from Nexicart- 2, the First U.S. Trial of a CAR-T (NXC-201) in Relapsed or Refractory (R/R) Light Chain (AL) Heather J. Landau, MD 1, Charlotte Hughes, MD 1, Aaron Seth Rosenberg, MD 2 , Mehrdad Abedi, MD 2 , Shahzad Raza, Slide 1 MD 3 , Jeffrey A. Zonder, MD 4 , Eug
Slide 2: Overview/Conclusion
Overview/ Conclusion • Initial results from Nexicart-2 suggest NXC-201 can be administered safe y & efficiently to patients with relapsed/refractory (R/R) AL amyloidosis Slide 2 • mild + manageable CRS and no neurotoxicity • 100% experienced rap·d and deep hematolog·c esponses • Organ responses in 8
Slide 3: Relapsed/Refractory AL Amyloidosis: ~23,000 U.S. Patients with No FDA Approved Drugs
Relapsed/Refractory AL Amyloidosis: ,v23,000 U.S. Patients with No FDA Approved Drugs 1 Light chains depos·t in organs, damaging organs Light chains produced by .. .. 2 2 Light chains misfold dysfunctiona l plasma Heart and aggregate cells in bone marrow • Heart failure r- • • Dangerous, irregular h
Slide 4: NXC-201: Sterically-Optimized CAR-T construct
NXC-201: Sterically-Optimized CAR-T construct N-GENIUS PLATFORM Sterically optimized key construct modifications Slide 4 Proprietary Optimized Proprietary Optimized Proprietary Optimized CD3 - "CD3(y" CDS Hinge Flexibility COBRA Binder ✓ Delivers "Digital" ✓ Enhances Plasma Cell Binding ✓ Reduces cy
Slide 5: NEXICART-2: First CAR-T Trial Designed For R/R AL Amyloidosis (NCT06097832)
NEXICART-2: First CAR-T Trial Designed For R/R AL Amyloidosis {NCT06097832) Study design • Open-label, single-arm, multi-site phase 1/2 study • n=40 patients Key criteria • Exposed to at least 1 line of therapy, including CD38 monoclonal antibody+ proteosome inhibitor Slide 5 • Measurable hematologi
Slide 6: NEXICART-2: Status
NEXICART-2: Status Open to accrual June 2024 Phase 1 ✓ Phase 2 Ongoing ➔ 25 more patients planned Slide 6 450 .X 10 6 (n=5*) 450 X 10 6 * 12 patients dosed at 450 x 106 including 7 + 5 from (n=7*) Phase 1 and 2, respectively No DLTs Data available as of cut-off April 11, 2025. Palladini G et al. JCO
Slide 7: NEXICART-2: Patient Characteristics
NEXICART-2: Patient Characteristics Median NX2-001 NX2-002 NX2-003 NX2-004 NX2-005 NX2-006 NX2-007 NX2-008 NX2-009 NX2-010 Age 56 67 82 64 62 72 66 63 80 67 (56-82) naer emale ale emale Fema e ale ale I ior lines of 4* 6** 2 4 4* 3 12* 4* 4* 3* 4 (2-12) ra 65 24 86 42 26 47 121 84 56 (24-121) M-spik
Slide 8: NEXICART-2: Safety
NEXICART-2: Safety CRS and ICANS reported according to ASTCT Consensus Grading CART Cell Dose 150 150 150 450 450 450 450 450 450 450 (x10 6 } CRS None None Grade 2 Grade 1 Grade 1 Grade 1 Grade 1 Grade 1 Grade 1 Grade 1 1 (1-2 CRS Onset None None 3 3 1 1 1 1 1 3 1 (1-3 ration None None 1 1 1 1 1 4
Slide 9: NEXICART-2: Results
NEXICART-2: Resu lts Data available as of cut-off April 11, 2025. Median follow up 121 days (range 29-289). Rapid normalization of pathologic paraprotein associated with organ responses NXC-201 dosi ng Best Respo nse ► 0% T 0.9 (1) C 250 NX2-002 -10% (1) Ill (U NVHA reduction 0.8 .c -20% II ➔ I E 0
Slide 10: In Patient's Own Words (day +15)
... In Patient's Own Words (day +15) ''Hi Dr Landau! Here we are a week tomorrow since I left the hospital (At day 10 after those magic CAR-T cells came on board)! Just had to tell you I've been wery happily & comfortably walking 2-3+ miles each day & doing great on the inclines (even the cross over
Slide 11: NEXICART-2: Hematologic responses reviewed by independent review committee
NEXICART-2: hematologic responses as reviewed by an independent review committee Data available as of cut-off April 11, 2025. Median follow up 121 days (range 29-289) . .................................................................subject ..#.......................................................
Slide 12: Conclusion
Conclusion • NXC-201 can be administered safely & efficiently to patients with R/R AL amyloidosis - population without a single FDA-approved treatment available - who have a true unmet medical need • Al (100%) received treatment with a vein-to-vein time 14 days • Low grade CRS and no neurotoxicity o
Slide 13: A Giant Thank You
A Giant Thank You .... ■ The research staff, clinical teams, apheresis units, cell therapy labs and investigators at each participating site ■ The patients and their families Slide 13 Thank you for your attent·on. Study was funded by: :§: l~~J~ ' NEXCELLA NIH/NCI Cancer Center Support Grant P30 CA00